Friday, 13 Jul 2018

You are here

Mixed Results with Combination Therapy in Gout

Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.

CRYSTAL was a 12 month study of 324 patients with tophaceous gout assessed the efficacy of lesinurad in combination with febuxostat. Patients were required to have an elevated serum urate (sUA) ≥8.0 mg/dl (or ≥6.0 mg/dl on ULT) and a measurable target tophus; and had to be on febuxostat 80mg daily for 3 weeks before randomization to lesinurad (200 or 400mg daily) or placebo.

Primary endpoint was achieving sUA <5.0 mg/dl by month 6 and the secondary end point was complete tophus resolution.

Significantly more patients achieved sUA < 5.0 with lesinurad 400mg (76.1%; P<0.0001) compared to placebo. The lesinurad 200mg dose was not significantly different (56.6%; P=0.13), than placebo and febuxostat (46.8%).

While tophus resolution on lesinurad was numerically (nearly 50% reduction) better than placebo at 12 months, this did not achieve statistical significance.

Safety findings were similar with the exception of higher rates of reversible serum creatinine elevation with lesinurad 400mg.

These data suggest that lesinurad in combination with febuxostat demonstrated superior sUA lowering compared with febuxostat alone, with clinically relevant impact on tophi resolution. 

The limited efficacy of the 200 mg dose and renal risks with the 400 mg dose of lesinurad may limit the use of this agent in many patients with gout.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Obesity, Hypertension and Diuretics Drive Gout Risk

A recent metanalysis suggests that obesity, hypertension and diuretic use are associated with a two-fold increased risk of incident gout.

From a potential of 9923 articles, researchers analyzed 11 studies with data suitable for the meta-analysis.

Gout was 2.24 times more likely to occur in individuals with body mass index ≥ 30 kg/m2 (adjusted relative risk 2.24 (95% confidence interval) 1.76–2.86).

Public Citizen Pressures FDA to Pull Febuxostat

Public Citizen has petitioned the U.S. Food and Drug Administration (FDA) to remove Takeda's drug febuxostat (Uloric) from the market, citing the FDA's own warnings and evidence of serious cardiovascular harms. This follows on a recent FDA safety warning and NEJM paper citing cardiovascular concerns over febuxostat.

Gout Takeaways

The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.

Sons of Gout Study

The genetics and heritability of gout has suggested a higher risk in certain families.  A UK cohort study examined the prevalence of gout and monosodium urate (MSU) crystal deposition among those at risk (sons of gout patients) for gout and found a high incidence of hyperuricemia and MSU crystal deposition.

The Hazardous Highs and Lows of Uric Acid

Both high and low levels of uric acid were linked with increased risks of death, showing a U-shaped association between serum uric acid levels and all-cause, cardiovascular, and cancer mortality, Korean researchers reported.